专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08933041B2 System for treating and preventing breast cancer 有权
标题翻译：用于治疗和预防乳腺癌的系统
公开(公告)号：US08933041B2
公开(公告)日：2015-01-13
申请号：US10579007
申请日：2004-11-12
申请人： Dennis L. Panicali , Gail P. Mazzara , Linda R. Gritz , Jeffrey Schlom , Kwong-Yok Tsang , James W. Hodge
发明人： Dennis L. Panicali , Gail P. Mazzara , Linda R. Gritz , Jeffrey Schlom , Kwong-Yok Tsang , James W. Hodge
IPC分类号： A61K48/00 , C12N15/863 , C12N15/12 , C12N15/86 , A61K39/00 , C12N7/00
CPC分类号： C12N15/86 , A61K39/0011 , A61K48/005 , A61K2039/53 , A61K2039/545 , A61K2039/55522 , C12N7/00 , C12N2710/24043 , C12N2710/24071 , C12N2710/24143 , C12N2710/24171 , C12N2799/023
摘要： The present invention is directed to a system for treating individuals at risk of or suffering from breast cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains in a foreign nucleic acid encoding at least one breast cancer antigen.
摘要翻译：本发明涉及用于治疗患有或患有乳腺癌的个体的系统。该系统包括向个体施用重组痘病毒，其中痘病毒含有编码至少一种乳腺癌抗原的外源核酸。

2. 发明申请

US20080166367A1 Custom Vectors for Treating and Preventing Pancreatic Cancer 有权
标题翻译：用于治疗和预防胰腺癌的定制载体
公开(公告)号：US20080166367A1
公开(公告)日：2008-07-10
申请号：US10579025
申请日：2004-11-12
申请人： Dennis L. Panicali , Gail P. Mazzara , Linda R. Gritz , Jeffrey Schlom , Kwong-Yok Tsang , James W. Hodge
发明人： Dennis L. Panicali , Gail P. Mazzara , Linda R. Gritz , Jeffrey Schlom , Kwong-Yok Tsang , James W. Hodge
IPC分类号： A61K39/275 , A61K39/00 , C07H21/04
CPC分类号： C12N15/86 , A61K39/0011 , A61K2039/53 , A61K2039/545 , A61K2039/55516 , C12N7/00 , C12N2710/24043 , C12N2710/24071 , C12N2710/24143 , C12N2710/24171
摘要： The present invention is directed to a system for treating individuals at risk of developing or suffering from pancreatic cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains a foreign nucleic acid encoding at least one pancreatic tumor associated antigen (PTAA).
摘要翻译：本发明涉及用于治疗患有胰腺癌发展或患有胰腺癌风险的个体的系统。该系统包括向个体施用重组痘病毒，其中痘病毒含有编码至少一种胰腺肿瘤相关抗原（PTAA）的外源核酸。

3. 发明授权

US08901093B2 Custom vectors for treating and preventing pancreatic cancer 有权
标题翻译：用于治疗和预防胰腺癌的定制载体
公开(公告)号：US08901093B2
公开(公告)日：2014-12-02
申请号：US10579025
申请日：2004-11-12
申请人： Dennis L. Panicali , Gail P. Mazzara , Linda R. Gritz , Jeffrey Schlom , Kwong-Yok Tsang , James W. Hodge
发明人： Dennis L. Panicali , Gail P. Mazzara , Linda R. Gritz , Jeffrey Schlom , Kwong-Yok Tsang , James W. Hodge
IPC分类号： A61K48/00 , C12N5/00 , C12N5/02 , C12N15/00 , A61K39/00 , A61K39/38 , A61K39/225 , A01N63/00 , A01N65/00 , C12N15/86 , C12N7/00
CPC分类号： C12N15/86 , A61K39/0011 , A61K2039/53 , A61K2039/545 , A61K2039/55516 , C12N7/00 , C12N2710/24043 , C12N2710/24071 , C12N2710/24143 , C12N2710/24171
摘要： The present invention is directed to a system for treating individuals at risk of developing or suffering from pancreatic cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains a foreign nucleic acid encoding at least one pancreatic tumor associated antigen (PTAA).
摘要翻译：本发明涉及用于治疗患有胰腺癌发展或患有胰腺癌风险的个体的系统。该系统包括向个体施用重组痘病毒，其中痘病毒含有编码至少一种胰腺肿瘤相关抗原（PTAA）的外源核酸。

4. 发明授权

US07410644B2 Recombinant pox virus for immunization against tumor-associated antigens 有权
标题翻译：重组痘病毒用于免疫肿瘤相关抗原
公开(公告)号：US07410644B2
公开(公告)日：2008-08-12
申请号：US10197127
申请日：2002-07-17
申请人： Jeffrey Schlom , Dennis L. Panicali , Linda R. Gritz , Gail P. Mazzara
发明人： Jeffrey Schlom , Dennis L. Panicali , Linda R. Gritz , Gail P. Mazzara
IPC分类号： A61K39/275 , A61K39/12
CPC分类号： C12N15/86 , A61K38/00 , C07K14/70503 , C12N2710/24043
摘要： Recombinant pox viruses capable of expressing cell-encoded, tumor-associated antigens are disclosed. The recombinant viruses are useful for evoking an immune response against the antigen.
摘要翻译：公开了能够表达细胞编码的肿瘤相关抗原的重组痘病毒。重组病毒可用于引发针对抗原的免疫应答。

5. 发明授权

US06319496B1 Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof 有权
标题翻译：癌细胞自身抗原特异性的人细胞毒性T细胞的产生及其用途
公开(公告)号：US06319496B1
公开(公告)日：2001-11-20
申请号：US09287221
申请日：1999-04-06
申请人： Dennis L. Panicali , Jeffrey Schlom
发明人： Dennis L. Panicali , Jeffrey Schlom
IPC分类号： A61K4800
CPC分类号： C07K14/705 , A61K39/00 , A61K2039/51 , C12N2799/023
摘要： We have discovered that by using a recombinant DNA viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding the carcinoma self-associated antigen, or a cytotoxic T-cell eliciting epitope thereof, operably linked to a promoter capable of expression in the host, human cytotoxic T-cells specific for the carcinoma self-associated antigens can be produced. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate production of cytotoxic T-cells, and contacting the host with additional antigen at periodic intervals thereafter. The additional antigen may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional antigen is added by contacting the host with antigen. The antigen may be formulated with an adjuvant or in a liposomal formulation. The T-cells can be isolated. The number of T-cells can be expanded by contacting the isolated cytotoxic T-cells alternately with the carcinoma self-associated antigen or an epitope thereof and IL-2. The isolated T-cells can be used in a method for treating a host having a tumor expressing a carcinoma self-associated antigen comprising introducing cytotoxic T-cells specific for the antigen to the host and at at least one periodic interval thereafter introducing to the host a T-cell eliciting epitope of the carcinoma self-associated antigen.
摘要翻译：我们已经发现，通过使用重组DNA病毒载体，优选具有至少一个插入位点的痘病毒载体，所述插入位点含有编码癌自身相关抗原的DNA区段或其启动子的细胞毒性T细胞诱导表位，可操作地连接到启动子能够在宿主中表达，可以产生对癌自身相关抗原特异性的人细胞毒性T细胞。该方法优选包括将足够量的重组痘病毒载体引入宿主以刺激细胞毒性T细胞的产生，并且此后以周期性间隔使宿主与另外的抗原接触。可以通过使用来自不同痘属的第二痘病毒载体添加另外的抗原。在另一个实施方案中，通过使宿主与抗原接触来加入另外的抗原。抗原可以用佐剂或脂质体制剂配制。可以分离T细胞。可以通过与分离的细胞毒性T细胞与癌自身相关抗原或其表位和IL-2交替接触来扩增T细胞的数量。分离的T细胞可以用于治疗具有表达癌自身相关抗原的肿瘤的宿主的方法，包括将对抗原特异性的细胞毒性T细胞引入宿主，并且至少在周期性间隔之后向宿主引入癌自身相关抗原的T细胞引发表位。

6. 发明授权

US6165460A Generation of immune responses to prostate-specific antigen (PSA) 失效
标题翻译：产生对前列腺特异性抗原（PSA）的免疫应答
公开(公告)号：US6165460A
公开(公告)日：2000-12-26
申请号：US500306
申请日：1995-07-10
申请人： Jeffrey Schlom , Dennis L. Panicali
发明人： Jeffrey Schlom , Dennis L. Panicali
IPC分类号： C12N15/09 , A61K39/00 , A61K48/00 , A61P35/00 , C07K14/47 , C07K16/40 , C12N9/64 , C12N15/00 , C12N15/57 , C12R1/92 , A01N63/00 , A61K35/12 , C12N15/63
CPC分类号： C07K14/4748 , A61K39/00 , A61K2039/5256 , A61K2039/55522 , A61K2039/55555 , C12N9/6445 , C12N2799/023 , C12N2799/026
摘要： We have discovered that by using a recombinant viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding prostate-specific antigen (PSA), operably linked to a promoter capable of expression in the host, a specific humoral and cellular immune response to PSA can be generated. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate the immune response, and contacting the host with additional PSA at periodic intervals thereafter. The additional PSA may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional PSA can be added by contacting the host with PSA by a variety of other methods, including in one preferred embodiment adding PSA. The PSA may be formulated with an adjuvant or in a liposomal formulation.
摘要翻译：我们已经发现，通过使用重组病毒载体，优选具有至少一个含有编码前列腺特异性抗原（PSA）的DNA区段的插入位点的痘病毒载体，其可操作地连接到能够在宿主中表达的启动子，特异性体液并且可以产生对PSA的细胞免疫应答。该方法优选包括将足够量的重组痘病毒载体引入宿主以刺激免疫应答，并且此后以周期性间隔使宿主与另外的PSA接触。可以通过使用来自不同痘属的第二痘病毒载体添加另外的PSA。在另一个实施方案中，可以通过各种其它方法，包括在一个优选实施方案中添加PSA将宿主与PSA接触来添加另外的PSA。 PSA可以用佐剂或脂质体制剂配制。

7. 发明授权

US07598225B1 Generation of immune response to prostate-specific antigen (PSA) 有权
标题翻译：产生对前列腺特异性抗原（PSA）的免疫应答
公开(公告)号：US07598225B1
公开(公告)日：2009-10-06
申请号：US09693121
申请日：2000-10-20
申请人： Jeffrey Schlom , Dennis L. Panicali
发明人： Jeffrey Schlom , Dennis L. Panicali
IPC分类号： A61K48/00
CPC分类号： C07K14/4748 , A61K39/00 , A61K2039/5256 , A61K2039/55522 , A61K2039/55555 , C12N9/6445 , C12N2799/023 , C12N2799/026
摘要： We have discovered that by using a recombinant viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding prostate-specific antigen (PSA), operably linked to a promoter capable of expression in the host, a specific humoral and cellular immune response to PSA can be generated. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate the immune response, and contacting the host with additional PSA at periodic intervals thereafter. The additional PSA may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional PSA can be added by contacting the host with PSA by a variety of other methods, including in one preferred embodiment adding PSA. The PSA may be formulated with an adjuvant or in a liposomal formulation.
摘要翻译：我们已经发现，通过使用重组病毒载体，优选具有至少一个含有编码前列腺特异性抗原（PSA）的DNA区段的插入位点的痘病毒载体，其可操作地连接到能够在宿主中表达的启动子，特异性体液并且可以产生对PSA的细胞免疫应答。该方法优选包括将足够量的重组痘病毒载体引入宿主以刺激免疫应答，并且此后以周期性间隔使宿主与另外的PSA接触。可以通过使用来自不同痘属的第二痘病毒载体添加另外的PSA。在另一个实施方案中，可以通过各种其它方法，包括在一个优选实施方案中添加PSA将宿主与PSA接触来添加另外的PSA。 PSA可以用佐剂或脂质体制剂配制。

8. 发明授权

US6001349A Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof 失效
标题翻译：癌细胞自身抗原特异性的人细胞毒性T细胞的产生及其用途
公开(公告)号：US6001349A
公开(公告)日：1999-12-14
申请号：US396385
申请日：1995-02-22
申请人： Dennis L. Panicali , Jeffrey Schlom
发明人： Dennis L. Panicali , Jeffrey Schlom
IPC分类号： C12N15/09 , A61K35/76 , A61K39/00 , A61K39/39 , A61K48/00 , A61P35/00 , C07K14/705 , C12N5/10 , C12N15/12 , A01N63/00
CPC分类号： C07K14/705 , A61K2039/51 , A61K39/00 , C12N2799/023
摘要： We have discovered that by using a recombinant DNA viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding the carcinoma self-associated antigen, or a cytotoxic T-cell eliciting epitope thereof, operably linked to a promoter capable of expression in the host, human cytotoxic T-cells specific for the carcinoma self-associated antigens can be produced. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate production of cytotoxic T-cells, and contacting the host with additional antigen at periodic intervals thereafter. The additional antigen may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional antigen is added by contacting the host with antigen. The antigen may be formulated with an adjuvant or in a liposomal formulation. The T-cells can be isolated. The number of T-cells can be expanded by contacting the isolated cytotoxic T-cells alternately with the carcinoma self-associated antigen or an epitope thereof and IL-2. The isolated T-cells can be used in a method for treating a host having a tumor expressing a carcinoma self-associated antigen comprising introducing cytotoxic T-cells specific for the antigen to the host and at at least one periodic interval thereafter introducing to the host a T-cell eliciting epitope of the carcinoma self-associated antigen.
摘要翻译：我们已经发现，通过使用重组DNA病毒载体，优选具有至少一个插入位点的痘病毒载体，所述插入位点含有编码癌自身相关抗原的DNA区段或其启动子的细胞毒性T细胞诱导表位，可操作地连接到启动子能够在宿主中表达，可以产生对癌自身相关抗原特异性的人细胞毒性T细胞。该方法优选包括将足够量的重组痘病毒载体引入宿主以刺激细胞毒性T细胞的产生，并且此后以周期性间隔使宿主与另外的抗原接触。可以通过使用来自不同痘属的第二痘病毒载体添加另外的抗原。在另一个实施方案中，通过使宿主与抗原接触来加入另外的抗原。抗原可以用佐剂或脂质体制剂配制。可以分离T细胞。可以通过与分离的细胞毒性T细胞与癌自身相关抗原或其表位和IL-2交替接触来扩增T细胞的数量。分离的T细胞可以用于治疗具有表达癌自身相关抗原的肿瘤的宿主的方法，包括将对抗原特异性的细胞毒性T细胞引入宿主，并且至少在周期性间隔之后向宿主引入癌自身相关抗原的T细胞引发表位。

9. 发明授权

US08957192B2 Human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1 有权
标题翻译：人类细胞毒性T淋巴细胞表位及其激动剂表位来自MUC-1的非可变数目的串联重复序列
公开(公告)号：US08957192B2
公开(公告)日：2015-02-17
申请号：US13176341
申请日：2011-07-05
申请人： Jeffrey Schlom , Kwong-Yok Tsang
发明人： Jeffrey Schlom , Kwong-Yok Tsang
IPC分类号： C07H21/02 , A61K39/00 , C07K14/47 , C07K14/705 , C12N15/85
CPC分类号： A61K39/0011 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , C07K14/4727 , C07K14/70596 , C12N15/85
摘要： Novel MUC-1 epitopes outside the VNTR region are identified. In addition, the first agonist epitope of MUC-1 is described. The employment of agonist epitopes in peptide, protein and vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers.
摘要翻译：鉴定出VNTR区以外的新型MUC-1表位。此外，描述了MUC-1的第一激动剂表位。在肽，蛋白质和基于载体的疫苗中使用激动剂表位可能有助于开发一系列人类癌症的有效疫苗。

10. 发明授权

US08748390B2 Immunogenic epitopes of NGEP antigen 有权
标题翻译： NGEP抗原的免疫原性表位
公开(公告)号：US08748390B2
公开(公告)日：2014-06-10
申请号：US13265490
申请日：2010-04-19
申请人： Jeffrey Schlom , Kwong-Yok Tsang , Ira Pastan
发明人： Jeffrey Schlom , Kwong-Yok Tsang , Ira Pastan
IPC分类号： A61K38/08 , A61K39/00 , C07K7/06
CPC分类号： A61K39/0011 , A61K38/00 , A61K38/191 , A61K38/193 , A61K38/20 , A61K38/217 , A61K39/00 , C07K7/06 , C07K14/4748 , C07K14/705 , Y02A50/466
摘要： The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.
摘要翻译：本发明提供了一种肽，其包含来自人肿瘤相关抗原（TAA）在前列腺中表达的新基因（NGEP）的人溶细胞T淋巴细胞（CTL）表位，其可用于预防或治疗前列腺癌，以及编码所述肽的核酸，包含所述核酸的载体，包含所述肽，核酸或载体的细胞及其组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式